Display options
Share it on

Clin Med Insights Case Rep. 2012;5:69-75. doi: 10.4137/CCRep.S9742. Epub 2012 May 21.

Paraganglioma of prostatic origin.

Clinical medicine insights. Case reports

B Padilla-Fernández, P Antúnez-Plaza, M F Lorenzo-Gómez, M Rodríguez-González, A Martín-Rodríguez, J M Silva-Abuín

Affiliations

  1. Department of Urology, University Hospital of Salamanca, Salamanca, Spain.

PMID: 22661903 PMCID: PMC3364107 DOI: 10.4137/CCRep.S9742

Abstract

INTRODUCTION: Paragangliomas are usually benign tumors arising from chromaffin cells located outside the adrenal gland. Prostatic paraganglioma is an unusual entity in adult patients, with only 10 cases reported in the medical literature.

CASE REPORT: A 34-year-old male with a history of chronic prostatitis consulted for perineal pain. On digital rectal examination the prostate was enlarged and firm, without nodules. The PSA level was 0.8 ng/mL and the catecholamines in the urine were elevated. On ultrasound a retrovesical 9 cm mass of undetermined origin measuring was present. A PET-CT scan showed a pelvic lesion measuring 9 cm with moderate increase in glucidic metabolism localized in the area of the prostate. A biopsy of the prostate revealed a neuroendocrine tumor, possibly a prostatic paraganglioma. A body scintigraphy with MIBG I-123 ruled out the presence of metastases or multifocal tumor. A radical prostatectomy with excision of the pelvic mass was performed under adrenergic blockade. One year after surgery the patient is asymptomatic and disease free.

DISCUSSION/CONCLUSIONS: Prostatic paraganglioma is a rare, usually benign tumor, which should be considered in the differential diagnosis of prostate tumors in young males. Its diagnosis is based on the determination of catecholamine in blood and 24-hour urine and in imaging studies principally scintigraphy with MIBG I-123. Diagnostic confirmation is by histopathological study. The treatment consists of radical resection under adrenergic blockade and volume expansion. Given the limited number of cases reported, it is difficult to establish prognostic factors. Malignancy is defined by clinical criteria, and requires life long follow-up.

Keywords: paraganglioma; prostate; prostate tumor

References

  1. Q J Nucl Med. 1997 Mar;41(1):36-41 - PubMed
  2. Urology. 2005 Sep;66(3):657 - PubMed
  3. J Urol. 1990 Nov;144(5):1219-21 - PubMed
  4. J Urol. 1992 Jan;147(1):1-10 - PubMed
  5. Scand J Urol Nephrol. 1997 Oct;31(5):501-3 - PubMed
  6. Ann N Y Acad Sci. 2006 Aug;1073:21-9 - PubMed
  7. Curr Treat Options Oncol. 2003 Aug;4(4):329-37 - PubMed
  8. Arch Pathol Lab Med. 2008 Aug;132(8):1272-84 - PubMed
  9. Clin Genitourin Cancer. 2012 Mar;10(1):54-6 - PubMed
  10. Urology. 2005 Jul;66(1):194 - PubMed
  11. J Urol. 2006 Jan;175(1):314 - PubMed
  12. Eur Urol. 2003 Dec;44(6):672-81 - PubMed
  13. J Pediatr Surg. 1994 Sep;29(9):1197-201 - PubMed
  14. Br J Urol. 1987 May;59(5):478-9 - PubMed
  15. J Urol. 1989 Jan;141(1):130-2 - PubMed
  16. Arch Pathol Lab Med. 2004 Aug;128(8):e104-6 - PubMed
  17. Hum Pathol. 1990 Nov;21(11):1168-80 - PubMed
  18. J Urol. 1999 Jun;161(6):1909-10 - PubMed
  19. J Urol. 1979 Mar;121(3):376-8 - PubMed
  20. J Natl Cancer Inst. 2003 Aug 20;95(16):1196-204 - PubMed
  21. Urology. 2001 Jun;57(6):1025-32 - PubMed
  22. Cancer. 1971 Oct;28(4):1063-73 - PubMed

Publication Types